Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 7,820 shares at $17.01 ($22K) on 2022-09-02, disclosed to the SEC on 2022-09-07.
Scheduled sale ($22k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 6,500 | $0 | 0.0% |
| 2 | $17.01 | 1,320 | $22K | 100.0% |
| Total | $2.87 avg | 7,820 | $22K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |